| |
Hepatitis C Vaccine Candidate
|
| |
| |
Press Release Source: ViRexx Medical Corp.
ViRexx To Present Data On Chimigen'TM' Vaccine At 12th International Symposium On Hepatitis C And Related Viruses
Monday October 3, 1:45 pm ET
EDMONTON, Alberta--(BUSINESS WIRE)--Oct. 3, 2005--ViRexx Medical Corp. (TSX:VIR - News), a company focused on immunotherapy treatments for cancer, chronic hepatitis B & C and embolotherapy treatments for tumors, announced that an abstract relating to pre-clinical data from a hepatitis C Chimigen(TM) vaccine candidate will be presented at the 12th International Symposium on Hepatitis C Virus and Related Viruses in Montreal, Canada.
The conference is being held from October 2 to October 6, 2005 in Montreal, (Quebec, Canada) at the Queen Elizabeth Hotel. Dr. Rajan George, Vice President, Research and Development, Infectious Diseases at ViRexx Medical Corp. will be presenting an abstract entitled "A Novel Dendritic Cell-Targeted Chimeric Therapeutic Vaccine for the Treatment of Chronic C Infection". The presentation will take place on Wednesday, October 5, 2005.
Marc Canton, President and Chief Operating Officer of ViRexx commented, "Dr. George will take this opportunity to review pre-clinical data from our novel Chimigen(TM) Vaccine for hepatitis C. The Chimigen(TM) technology platform aims to treat patients who are chronically infected with hepatitis B or hepatitis C. As part of our ongoing clinical development program, we intend to advance a hepatitis B Chimigen(TM) vaccine into the clinic later this year and select a vaccine candidate for clinical development for hepatitis C."
About ViRexx Medical Corp.
ViRexx is an Edmonton, Alberta based biotechnology company focused on the development of novel therapeutic products for the treatment of certain cancers and specified chronic viral infections. ViRexx's most advanced programs include drug candidates for the treatment of ovarian cancer, chronic hepatitis B & C and solid tumors.
ViRexx's lead product, OvaRex® MAb, a therapy for the treatment of late-stage ovarian cancer, is currently the subject of a Phase III clinical trial being funded by ViRexx's licensing partner Unither Pharmaceuticals, Inc., a subsidiary of United Therapeutics Corporation. For additional information about ViRexx, please see www.virexx.com.
THE TSX HAS NOT APPROVED OR DISAPPROVED OF THE INFORMATION CONTAIN ED HEREIN
ViRexx Medical Corp. (TSX:VIR - News)
Contact:
ViRexx Medical Corp.
Rob Salmon
Chief Financial Officer
(780) 989-6708
Fax: (780) 436-0068
rsalmon@virexx.com
OR
The Equicom Group Inc.
Ross Marshall
Investor Relations
(800) 385 5451 ext. 238
Fax: (416) 815-0080
rmarshall@equicomgroup.com
OR
Lippert/Heilshorn & Associates Inc.
Kim Golodetz
Investor Relations
(212) 838 -3777
Fax: (212) 838 -4568
kgolodetz@lhai.com
Source: ViRexx Medical Corp.
|
|
| |
| |
|
|
|
